

Sheet 1 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50304/112001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/566,851
		Applicant SAINT-REMY et al.
		371(c) Date February 1, 2006
		Group 1644
(37 C.F.R. § 1.98(b))		IDS Filed March 26, 2010

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
/MS/	6,127,337	October 3, 2000	KONISHI et al.
	7,214,785	May 8, 2007	NAKASHIMA et al.
	2001/0018052	August 30, 2001	FEUERSTEIN
	2004/0120951	June 24, 2004	NAKASHIMA et al.
	2006/0292149	December 28, 2006	SAINT-REMY et al.
/MS/	2008/0206254	August 28, 2008	JACQUEMIN

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
/MS/	EP 1 222 929	July 17, 2002	EPO	
	WO 01/04269	January 18, 2001	WIPO	
	WO 02/101040	December 19, 2002	WIPO	English Language Abstract
	WO 2005/016455	February 24, 2005	WIPO	
	WO 2005/046583	May 26, 2005	WIPO	
/MS/	WO 2007/017154	February 15, 2007	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/MS/	ALGIMAN et al., "Natural Antibodies to Factor VIII (Anti-Hemophilic Factor) in Healthy Individuals," <i>Proc. Natl. Acad. Sci. USA</i> 89(9):3795-3799 (1992).
/MS/	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> 233(4765):747-753 (1986).

EXAMINER	/Michael Szperka/	DATE CONSIDERED	04/02/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

Sheet 2 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/112001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/566,851
		Applicant	SAINT-REMY et al.
		371(c) Date	February 1, 2006
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	March 26, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/MS/	CAMPBELL, <i>General Properties and Applications of Monoclonal Antibodies</i> , In <i>Monoclonal Antibody Technology</i> (Amsterdam, The Netherlands: Elsevier Science Publishers, 1984), Chapter 1, section 1.1, pages 1-4.
	CHATELLIER et al., "Codon Based Combinatorial Alanine Scanning Site-Directed Mutagenesis: Design, Implementation, and Polymerase Chain Reaction Screening," <i>Anal. Biochem.</i> 229(2):282-290 (1995).
	DAVIES and RIECHMANN, "Affinity Improvement of Single Antibody VH Domains: Residues in All Three Hypervariable Regions Affect Antigen Binding," <i>Immunotechnology</i> 2(3):169-179 (1996).
	FAY and SCANDELLA, "Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction Between the Subunit and Factor IXa," <i>J. Biol. Chem.</i> 274(42):29826-29830 (1999).
	FOSTER et al., "An Immunogenic Region within Residues Val ¹⁶⁷⁰ -Glu ¹⁶⁸⁴ of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding of Factor VIII to von Willebrand Factor," <i>J. Biol. Chem.</i> 263(11):5230-5234 (1988).
	FUKUI et al., "Laboratory Evidence of DIC Under FEIBA Treatment of a Hemophilic Patient with Intracranial Bleeding and High Titre Factor VIII Inhibitor," <i>Thromb. Res.</i> 22(1-2):177-184 (1981).
	FULCHER et al., "Human Factor VIII Procoagulant Protein. Monoclonal Antibodies Define Precursor-Product Relationships and Functional Epitopes," <i>J. Clin. Invest.</i> 76(1):117-124 (1985).
	GILLES et al., "Neutralizing Antiidiotypic Antibodies to Factor VIII Inhibitors After Desensitization in Patients with Hemophilia A," <i>J. Clin. Invest.</i> 97(6):1382-1388 (1996).
	GILLES et al., "Factor VIII Inhibitors." <i>Thromb. Haemost.</i> 78(1):641-646 (1997).
	GILLES et al., "Antibodies to Idiotypes of Human Monoclonal Anti-Factor VIII (FVIII) Antibodies Neutralise Their Inhibitory Activity," <i>Blood</i> 94, No.10(Suppl 1), p460a, abstract 2048 (1999).
	HEALEY et al., "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII," <i>J. Biol. Chem.</i> 270(24):14505-14509 (1995).
	HOLT et al., "Domain Antibodies: Proteins for Therapy," <i>Trends Biotechnol.</i> 21(11):484-490 (2003).
	JACQUEMIN et al., "Mutation Arg2150 → His in the Factor VIII C1 Domain Alters the Binding of Factor VIII to von Willebrand Factor and Is Responsible for a Mild Hemophilia A Phenotype," <i>Blood</i> 92:10(Suppl.1), Part 1-2:710 Abstract #2917 (1998).
	KAUFMAN et al., "Synthesis, Processing, and Secretion of Recombinant Human Factor VIII Expressed in Mammalian Cells," <i>J. Biol. Chem.</i> 263(13):6352-6362 (1988).
/MS/	LENTING et al., "The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-Related Protein," <i>J. Biol. Chem.</i> 274(34):23734-23739 (1999).

EXAMINER	/Michael Szperka/	DATE CONSIDERED	04/02/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

Sheet 3 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant 371(c) Date Group IDS Filed	50304/112001 10/566,851 SAINT-REMY et al. February 1, 2006 1644 March 26, 2010
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/MS/	LOLLAR et al., "Inhibition of Human Factor VIIIa by Anti-A2 Subunit Antibodies," <i>J. Clin. Invest.</i> 93(6): 2497-2504 (1997).
	LUBAHN and REISNER, "Characterization of a Monoclonal Anti-Idiotype Antibody to Human Anti-Factor VIII Antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 87(21):8232-8236 (1990).
	MANIVEL et al., "Maturation of an Antibody Response Is Governed by Modulations in Flexibility of the Antigen-Combining Site," <i>Immunity</i> 13(5):611-620 (2000).
	MÜHLE et al., "Epitope Mapping of Polyclonal Clotting Factor VIII-Inhibitory Antibodies Using Phage Display," <i>Thromb. Haemost.</i> 91(3):619-625 (2004).
	NYSTRÖM, "The Systemic Inflammatory Response Syndrome: Definitions and Aetiology," <i>J. Antimicrob. Chemother.</i> 41 Suppl A:1-7 (1998).
	OWENS and YOUNG, "The Genetic Engineering of Monoclonal Antibodies," <i>J. Immunol. Methods</i> 168(2):149-165 (1994).
	PRATT et al., "Structure of the C2 Domain of Human Factor VIII at 1.5 Å Resolution," <i>Nature</i> 402(6760):439-442 (1999).
	PRECUP et al., "A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage," <i>Blood</i> 77(9):1929-1936 (1991).
	SAENKO et al., "Role of the Low Density Lipoprotein-Related Protein Receptor in Mediation of Factor VIII Catabolism," <i>J. Biol. Chem.</i> 274(53):37685-37692 (1999).
	SAINT-REMY et al., "Anti-Idiotypic Antibodies: From Regulation to Therapy of Factor VIII Inhibitors," <i>Vox Sang.</i> 77 Suppl 1:21-24 (1999).
	SAWAMOTO et al., "Anti-Factor VIII Inhibitor Alloantibodies Recognizing the A2 Domain in the Human Factor VIII Heavy Chain Poorly Bind to Porcine Factor VIII," <i>Int. J. Hematol.</i> 65(2):151-158 (1997).
	SHIMA et al., "A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine," <i>Thromb. Haemost.</i> 69(3):240-246 (1993).
	SPIEGEL et al., "Structure of a Factor VIII C2 Domain-Immunoglobulin G4{Kappa} Fab Complex: Identification of an Inhibitory Antibody Epitope on the Surface of Factor VIII" <i>Blood</i> 98(1):13-19 (2001).
	STOILOVA-MCPHIE et al., "3-Dimensional Structure of Membrane-Bound Coagulation Factor VIII: Modeling of the Factor VIII Heterodimer within a 3-Dimensional Density Map Derived by Electron Crystallography," <i>Blood</i> 99(4):1215-1223 (2002).
/MS/	SULTAN et al., "Recovery From Anti-VIII:C (Antihemophilic Factor) Autoimmune Disease Is Dependent on Generation of Antiidiotypes Against Anti-VIII:C Autoantibodies," <i>Proc. Natl. Acad. Sci. USA</i> 84(3):828-831 (1987).

EXAMINER <i>/Michael Szperka/</i>	DATE CONSIDERED 04/02/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 4 of 4

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/112001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/566,851
		Applicant	SAINT-REMY et al.
		371(c) Date	February 1, 2006
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	March 26, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/MS/	VAN DEN BRINK et al., "Molecular Analysis of Human Anti-Factor VIII Antibodies by V Gene Phage Display Identifies a New Epitope in the Acidic Region Following the A2 Domain," <i>Blood</i> 96(2):540-545 (2000).
/MS/	VAN DEN BRINK et al., "Two Classes of Germline Genes Both Derived from the VH1 Family Direct the Formation of Human Antibodies that Recognize Distinct Antigenic Sites in the C2 Domain of Factor VIII," <i>Blood</i> 99(8):2828-2834 (2002).
/MS/	WILBUR and LIPMAN et al., "Rapid Similarity Searches of Nucleic Acid and Protein Data Banks," <i>Proc. Natl. Acad. Sci. USA</i> 80(3):726-730 (1983).

EXAMINER	/Michael Szperka/	DATE CONSIDERED	04/02/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			